Literature DB >> 33496101

[Analysis of classical prescription Jinshui Liujun Jian based on ancient literature].

Zi-Liang Dong1, Hong-Liang Li1, Wei-Zao Luo1, Yao Qin1, Qi-Nan Yu1, Shi-Lu Peng1, Xin Wang2, Rui-Jun Wu2, Shi-Qi Liu1, Tao Peng1, Jing Huang1, Yu-Ling Qing1, Shao-Rong Qin1, Rui-Chao Xu1.   

Abstract

To provide the ancient literary evidence support for the clinical application and development of classical prescription based on systematical collection and analysis of the ancient Chinese medical literature containing Jinshui Liujun Jian, including its origin and development. Bibliometric analysis was used and information of Jinshui Liujun Jian in ancient Chinese medical literature was then collected for statistical analysis of formula compositions, main indications, dosage, preparation methods, etc. A total of 151 valid items of data were obtained from 48 ancient Chinese medicine books. Jinshui Liujun Jian was first recorded in Jingyue Quanshu written by ZHANG Jiebin. This prescription consisted of Rehmanniae Radix Praeparata, Angelicae Sinensis Radix, Pinelliae Rhizome, Citri Reticulatae Pericarpium, Poria and Glycyrrhizae Radix et Rhizome Praeparata cum Melle, and it was mainly used to treat the deficiency of lung and kidney, edema and excess production of phlegm, or Yin deficiency in the old, insufficient blood-qi, wind-cold evil, cough and disgusting, asthma and excessive phlegm. Doctors in later dynasties mostly followed the prescription compositions, dosages and indications in Jingyue Quanshu, and extended the clinical application of this prescription.

Entities:  

Keywords:  Jinshui Liujun Jian; classical prescription; dose; evolutionof formula meaning; literature analysis

Year:  2020        PMID: 33496101     DOI: 10.19540/j.cnki.cjcmm.20200424.306

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  1 in total

1.  Analysis of Clinical Characteristics and Psychoacoustic Indexes in Different TCM Syndromes of Idiopathic Tinnitus.

Authors:  Yan Niu; Jinmei Ning; Shubo Zhao; Chao Fang
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-25       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.